insights_auto
Why is AIM up 4.01%?
Dive Deeperchevron_right
AIM:NYSEAMERICAN
AIM ImmunoTech Inc
$0.16
arrow_upward
+4.01%(+0.0062) 1D
$0.16
arrow_upward
+0.03% (+0.000050)todayPre-market
Closed: Nov 2, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AIM...
Open
$0.16
High
$0.17
Low
$0.16
Mkt. cap
6.60M
Avg. vol.
888.09K
Volume
4.43K
52-wk high
$2.10
52-wk low
$0.15
EPS
-$3.93
Beta
1.27
Shares outstanding
39.90M
No. of employees
20
Open
$0.16
High
$0.17
Low
$0.16
Mkt. cap
6.60M
Avg. vol.
888.09K
Volume
4.43K
52-wk high
$2.10
52-wk low
$0.15
EPS
-$3.93
Beta
1.27
Shares outstanding
39.90M
No. of employees
20
News stories
From web sources and news partners
Tech Times
·
3 minutes ago
Broadridge Joins NYSE Tokenized Platform, Bringing Proxy Voting On-Chain
MarketWatch
·
18 minutes ago
This signal from the corporate bond market has historically preceded big drawdowns for the S&P 500
Investing.com
·
29 minutes ago
Nasdaq sank -5.3%, but these AI strategies surged up to +9.3% in October
The Motley Fool
·
49 minutes ago
The Company Behind the New York Stock Exchange Is Now Building on Hyperliquid. Here's What It Means for Investors.
Profile
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
About AIM ImmunoTech Inc
CEO-
Employees20
Founded1966
HeadquartersPhiladelphia, Pennsylvania, United States
SectorBiotechnology
Websiteaimimmuno.com